Eyal Attar
Chief Tech/Sci/R&D Officer chez VOR BIOPHARMA INC.
Fortune : 267 569 $ au 31/03/2024
Profil
Eyal C.
Attar is currently the Chief Medical Officer at Vor Biopharma, Inc. Prior to this, he worked as the Senior Medical Director at Agios Pharmaceuticals, Inc. from 2016 to 2019.
He also served as the Chief Medical Officer & Senior Vice President at Aprea Therapeutics, Inc. Dr. Attar's education includes a doctorate degree from UNC School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0,17% | 06/02/2024 | 112 853 ( 0,17% ) | 267 462 $ | 31/03/2024 |
APREA THERAPEUTICS, INC.
0,00% | 26/06/2023 | 16 ( 0,00% ) | 107 $ | 31/03/2024 |
Postes actifs de Eyal Attar
| Sociétés | Poste | Début |
|---|---|---|
| VOR BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 12/10/2022 |
Anciens postes connus de Eyal Attar
| Sociétés | Poste | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2019 |
| Harvard Medical School | Corporate Officer/Principal | - |
| APREA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Eyal Attar
| UNC School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
